About this Journal Submit a Manuscript Table of Contents
ISRN Radiology
Volume 2013 (2013), Article ID 496438, 21 pages
http://dx.doi.org/10.5402/2013/496438
Review Article

Radiographic Contrast-Media-Induced Acute Kidney Injury: Pathophysiology and Prophylactic Strategies

Department of Surgery, Cambridge Vascular Unit, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Box 201, Cambridge CB2 0QQ, UK

Received 16 June 2013; Accepted 14 July 2013

Academic Editors: M. Brodmann, G. Crisi, and G. Korosoglou

Copyright © 2013 Umar Sadat. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. H. Lameire, “Contrast-induced nephropathy-prevention and risk reduction,” Nephrology Dialysis Transplantation, vol. 21, no. 1, pp. i11–i23, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. B. J. Barrett, “Contrast nephrotoxicity,” Journal of the American Society of Nephrology, vol. 5, no. 2, pp. 125–137, 1994. View at Scopus
  3. M. W. Rich and C. A. Crecelius, “Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study,” Archives of Internal Medicine, vol. 150, no. 6, pp. 1237–1242, 1990. View at Publisher · View at Google Scholar · View at Scopus
  4. C. P. Taliercio, R. E. Vlietstra, L. D. Fisher, and J. C. Burnett, “Risks for renal dysfunction with cardiac angiography,” Annals of Internal Medicine, vol. 104, no. 4, pp. 501–504, 1986. View at Scopus
  5. P. S. Pafrey, S. M. Griffiths, B. J. Barrett et al., “Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study,” New England Journal of Medicine, vol. 320, no. 3, pp. 143–149, 1989. View at Scopus
  6. P. M. Palevsky, “Defining contrast-induced nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 7, pp. 1151–1153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. B. J. Barrett and P. S. Parfrey, “Prevention of nephrotoxicity induced by radiocontrast agents,” New England Journal of Medicine, vol. 331, no. 21, pp. 1449–1450, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Gabriel, “Time to scrap creatinine clearance?” British Medical Journal, vol. 293, no. 6555, pp. 1119–1120, 1986. View at Scopus
  9. W. F. Finn, “The clinical and renal consequences of contrast-induced nephropathy,” Nephrology Dialysis Transplantation, vol. 21, no. 1, pp. i2–i10, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. “K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” American Journal of Kidney Diseases, vol. 39, no. 2, supplement 1, pp. S1–S266, 2002. View at Publisher · View at Google Scholar
  11. S. D. Weisbord, K. E. Kip, M. I. Saul, and P. M. Palevsky, “Defining clinically significant radiocontrast nephropathy,” Journal of the American Society of Nephrology, vol. 14, pp. 280A–281A, 2003.
  12. D. W. Cockcroft and M. H. Gault, “Prediction of creatinine clearance from serum creatinine,” Nephron, vol. 16, no. 1, pp. 31–41, 1976. View at Scopus
  13. M. R. Rudnick, S. Goldfarb, L. Wexler et al., “Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial,” Kidney International, vol. 47, no. 1, pp. 254–261, 1995. View at Scopus
  14. P. Aspelin, P. Aubry, S. Fransson, R. Strasser, R. Willenbrock, and K. J. Berg, “Nephrotoxic effects in high-risk patients undergoing angiography,” New England Journal of Medicine, vol. 348, no. 6, pp. 491–499, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. G. J. Merten, W. P. Burgess, L. V. Gray et al., “Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial,” Journal of the American Medical Association, vol. 291, no. 19, pp. 2328–2334, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Mueller, G. Buerkle, H. J. Buettner et al., “Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty,” Archives of Internal Medicine, vol. 162, no. 3, pp. 329–336, 2002. View at Scopus
  17. E. M. Levy, C. M. Viscoli, and R. I. Horwitz, “The effect of acute renal failure on mortality: a cohort analysis,” Journal of the American Medical Association, vol. 275, no. 19, pp. 1489–1494, 1996. View at Publisher · View at Google Scholar · View at Scopus
  18. K. J. Berg, “Nephrotoxicity related to contrast media,” Scandinavian Journal of Urology and Nephrology, vol. 34, no. 5, pp. 317–322, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Iakovou, G. Dangas, R. Mehran et al., “Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention,” Journal of Invasive Cardiology, vol. 15, no. 1, pp. 18–22, 2003. View at Scopus
  20. S. H. Hou, D. A. Bushinsky, and J. B. Wish, “Hospital-acquired renal insufficiency: a prospective study,” American Journal of Medicine, vol. 74, no. 2, pp. 243–248, 1983. View at Scopus
  21. K. Nash, A. Hafeez, and S. Hou, “Hospital-acquired renal insufficiency,” American Journal of Kidney Diseases, vol. 39, no. 5, pp. 930–936, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. S. K. Morcos, “Contrast-induced nephropathy: are there differences between low osmolar and iso-osmolar iodinated contrast media?” Clinical Radiology, vol. 64, no. 5, pp. 468–472, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Seeliger, M. Sendeski, C. S. Rihal, and P. B. Persson, “Contrast-induced kidney injury: mechanisms, risk factors, and prevention,” European Heart Journal, vol. 33, no. 16, pp. 2007–2015, 2012.
  24. U. Ludwig, J. Connemann, and F. Keller, “Effect of low-osmolar contrast medium iopromide and iso-osmolar iodixanol on DNA fragmentation in renal tubular cell culture,” Clinical and Experimental Nephrology, 2013.
  25. N. F. Fanning, B. J. Manning, J. Buckley, and H. P. Redmond, “Iodinated contrast media induce neutrophil apoptosis through a mitochondrial and caspase mediated pathway,” British Journal of Radiology, vol. 75, no. 899, pp. 861–873, 2002. View at Scopus
  26. M. M. Sendeski, “Pathophysiology of renal tissue damage by iodinated contrast media,” Clinical and Experimental Pharmacology and Physiology, vol. 38, no. 5, pp. 292–299, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Rackur, “New aspects of mechanism of action of povidone-iodine,” Journal of Hospital Infection, vol. 6, pp. 13–23, 1985. View at Scopus
  28. M. Naziroglu, N. Yoldas, E. N. Uzgur, and M. Kayan, “Role of contrast media on oxidative stress, Ca(2+) signaling and apoptosis in kidney,” The Journal of Membrane Biology, vol. 246, no. 2, pp. 91–100, 2013. View at Publisher · View at Google Scholar
  29. A. Peer, Z. Averbukh, S. Berman, D. Modai, M. Averbukh, and J. Weissgarten, “Contrast media augmented apoptosis of cultured renal mesangial, tubular, epithelial, endothelial, and hepatic cells,” Investigative Radiology, vol. 38, no. 3, pp. 177–182, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Potier, I. Lagroye, B. Lakhdar, J. Cambar, and J. Idee, “Comparative cytotoxicity of low- and high-osmolar contrast media to human fibroblasts and rat mesangial cells in culture,” Investigative Radiology, vol. 32, no. 10, pp. 621–626, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Haller, C. S. Schick, M. Zorn, and W. Kübier, “Cytotoxicity of radiocontrast agents on polarized renal epithelial cell monolayers,” Cardiovascular Research, vol. 33, no. 3, pp. 655–665, 1997. View at Publisher · View at Google Scholar · View at Scopus
  32. W. Furuta, A. Yamauchi, S. Dohgu et al., “Contrast media increase vascular endothelial permeability by inhibiting nitric-oxide production,” Investigative Radiology, vol. 37, no. 1, pp. 13–19, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. S. N. Heyman, B. A. Clark, N. Kaiser et al., “Radiocontrast agents induce endothelin Release in vivo and in vitro,” Journal of the American Society of Nephrology, vol. 3, no. 1, pp. 58–65, 1992. View at Scopus
  34. M. Wasaki, J. Sugimoto, and K. Shirota, “Glucose alters the susceptibility of mesangial cells to contrast media,” Investigative Radiology, vol. 36, no. 7, pp. 355–362, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. M. M. Sendeski, “Pathophysiology of renal tissue damage by iodinated contrast media,” Clinical and Experimental Pharmacology and Physiology, vol. 38, no. 5, pp. 292–299, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Nygren, H. R. Ulfendahl, P. Hansell, and U. Erikson, “Effects of intravenous contrast media on cortical and medullary blood flow in the rat kidney,” Investigative Radiology, vol. 23, no. 10, pp. 753–761, 1988. View at Scopus
  37. P. Liss, “Effects of contrast media on renal microcirculation and oxygen tension. An experimental study in the rat,” Acta Radiologica, vol. 38, supplement 409, pp. 7–29, 1997. View at Scopus
  38. Y. Zhang, J. Wang, X. Yang, et al., “The serial effect of iodinated contrast media on renal hemodynamics and oxygenation as evaluated by ASL and BOLD MRI,” Contrast Media & Molecular Imaging, vol. 7, no. 4, pp. 418–425, 2012.
  39. T. L. Pallone, Z. Zhang, and K. Rhinehart, “Physiology of the renal medullary microcirculation,” American Journal of Physiology, vol. 284, no. 2, pp. F253–F266, 2003. View at Scopus
  40. M. Sendeski, A. Patzak, T. L. Pallone, C. Cao, A. E. Persson, and P. B. Persson, “Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy,” Radiology, vol. 251, no. 3, pp. 697–704, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. S. N. Heyman, S. Rosen, M. Khamaisi, J. Idée, and C. Rosenberger, “Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy,” Investigative Radiology, vol. 45, no. 4, pp. 188–195, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Sendeski, A. Patzak, and P. B. Persson, “Constriction of the vasa recta, the vessels supplying the area at risk for acute kidney injury, by four different iodinated contrast media, evaluating ionic, nonionic, monomeric and dimeric agents,” Investigative Radiology, vol. 45, no. 8, pp. 453–457, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Aspelin, P. E. Nilsson, H. Schmid-Schönbein, S. Schröder, and R. Simon, “Effect of four non-ionic contrast media on red blood cells in vitro. I. Morphology,” Acta Radiologica, vol. 370, pp. 79–83, 1987. View at Scopus
  44. P. Aspelin, P. E. Nilsson, H. Schmid-Schönbein, S. Schröder, and R. Simon, “Effect of four non-ionic contrast media on red blood cells in vitro. II. Aggregation,” Acta Radiologica, vol. 370, pp. 85–87, 1987. View at Scopus
  45. P. Aspelin, P. E. Nilsson, H. Schmid-Schönbein, S. Schröder, and R. Simon, “Effect of four non-ionic contrast media on red blood cells in vitro. III. Deformability,” Acta Radiologica, vol. 370, pp. 89–91, 1987. View at Scopus
  46. K. Katsanos, A. Moutzouri, D. Karnabatidis, D. Siablis, and G. Athanassiou, “Influence of contrast media on red blood cell deformability,” Clinical Hemorheology and Microcirculation, vol. 39, no. 1–4, pp. 87–91, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Mrowietz, B. Hiebl, R. P. Franke, J.-W. Park, and F. Jung, “Reversibility of echinocyte formation after contact of erythrocytes with various radiographic contrast media,” Clinical Hemorheology and Microcirculation, vol. 39, no. 1–4, pp. 281–286, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Song, X. Wang, X. Xu, et al., “The effects of non-ionic contrast medium on the hemorheology in vitro and in vivo,” Clinical Hemorheology and Microcirculation, 2012.
  49. D. C. Lenhard, H. Pietsch, M. A. Sieber, et al., “The osmolality of nonionic, iodinated contrast agents as an important factor for renal safety,” Investigative Radiology, vol. 47, no. 9, pp. 503–510, 2012. View at Publisher · View at Google Scholar
  50. E. Seeliger, K. Becker, M. Ladwig, T. Wronski, P. B. Persson, and B. Flemming, “Up to 50-fold increase in urine viscosity with iso-osmolar contrast media in the rat,” Radiology, vol. 256, no. 2, pp. 406–414, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. G. Jost, D. C. Lenhard, M. A. Sieber, P. Lengsfeld, J. Hütter, and H. Pietsch, “Changes of renal water diffusion coefficient after application of iodinated contrast agents: effect of viscosity,” Investigative Radiology, vol. 46, no. 12, pp. 796–800, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Singh and A. Daftary, “Iodinated contrast media and their adverse reactions,” Journal of Nuclear Medicine Technology, vol. 36, no. 2, pp. 69–74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. M. L. Kinnison, N. R. Powe, and E. P. Steinberg, “Results of randomized controlled trials of low- versus high-osmolality contrast media,” Radiology, vol. 170, no. 2, pp. 381–389, 1989. View at Scopus
  54. B. J. Barrett and E. J. Carlisle, “Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media,” Radiology, vol. 188, no. 1, pp. 171–178, 1993. View at Scopus
  55. R. Solomon, “The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients,” Kidney International, vol. 68, no. 5, pp. 2256–2263, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Solomon and W. DuMouchel, “Contrast media and nephropathy: findings from systematic analysis and food and drug administration reports of adverse effects,” Investigative Radiology, vol. 41, no. 8, pp. 651–660, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. M. C. Heinrich, L. Häberle, V. Müller, W. Bautz, and M. Uder, “Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials,” Radiology, vol. 250, no. 1, pp. 68–86, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. P. Capasso and S. D. Weisbord, “Comment on meta-analyses of trials comparing contrast media,” Radiology, vol. 252, no. 1, p. 316, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Reed, P. Meier, U. U. Tamhane, K. B. Welch, M. Moscucci, and H. S. Gurm, “The relative renal safety of iodixanol compared with low-osmolar contrast media. A meta-analysis of randomized controlled trials,” JACC: Cardiovascular Interventions, vol. 2, no. 7, pp. 645–654, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. H. S. Thomsen and S. K. Morcos, “Contrast-medium-induced nephropathy: is there a new consensus? A review of published guidelines,” European Radiology, vol. 16, no. 8, pp. 1835–1840, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. F. Stacul, A. J. Van Der Molen, P. Reimer et al., “Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines,” European Radiology, vol. 21, no. 12, pp. 2527–2541, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. R. W. Katzberg and J. H. Newhouse, “Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe?” Radiology, vol. 256, no. 1, pp. 21–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. R. W. Katzberg and R. Lamba, “Contrast-induced nephropathy after intravenous administration: fact or fiction?” Radiologic Clinics of North America, vol. 47, no. 5, pp. 789–800, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. P. A. McCullough, R. Wolyn, L. L. Rocher, R. N. Levin, and W. W. O'Neill, “Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality,” American Journal of Medicine, vol. 103, no. 5, pp. 368–375, 1997. View at Publisher · View at Google Scholar · View at Scopus
  65. L. Gruberg, G. S. Mintz, R. Mehran et al., “The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency,” Journal of the American College of Cardiology, vol. 36, no. 5, pp. 1542–1548, 2000. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Martensson, S. Xu, M. Bell, C. R. Martling, and P. Venge, “Immunoassays distinguishing between HNL/NGAL released in urine from kidney epithelial cells and neutrophils,” Clinica Chimica Acta, vol. 413, no. 19-20, pp. 1661–1667, 2012.
  67. R. P. Karlsberg, S. Y. Dohad, and R. Sheng, “Contrast mediuminduced acute kidney injury: comparison of intravenous and intraarterial administration of iodinated contrast medium,” Journal of Vascular and Interventional Radiology, vol. 22, no. 8, pp. 1159–1165, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. W. K. Laskey, C. Jenkins, F. Selzer et al., “Volume-to-creatinine clearance ratio. A pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention,” Journal of the American College of Cardiology, vol. 50, no. 7, pp. 584–590, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. P. T. Johnson, D. Naidich, and E. K. Fishman, “MDCT for suspected pulmonary embolism: multi-institutional survey of 16-MDCT data acquisition protocols,” Emergency Radiology, vol. 13, no. 5, pp. 243–249, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. S. A. Nguyen, P. Suranyi, J. G. Ravenel et al., “Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function,” Radiology, vol. 248, no. 1, pp. 97–105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Tepel, M. Van Der Giet, C. Schwarzfeld, U. Laufer, D. Liermann, and W. Zidek, “Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine,” New England Journal of Medicine, vol. 343, no. 3, pp. 180–184, 2000. View at Publisher · View at Google Scholar · View at Scopus
  72. J. A. Hill, M. Winniford, M. B. Cohen et al., “Multicenter trial of ionic versus nonionic contrast media for cardiac angiography. The Iohexol Cooperative Study,” The American Journal of Cardiology, vol. 72, no. 11, pp. 770–775, 1993. View at Publisher · View at Google Scholar
  73. M. Dong, Z. Jiao, T. Liu, F. Guo, and G. Li, “Effect of administration route on the renal safety of contrast agents: a meta-analysis of randomized controlled trials,” Journal of Nephrology, vol. 25, no. 3, pp. 290–301, 2012.
  74. R. A. Mason, L. A. Arbeit, and F. Giron, “Renal dysfunction after arteriography,” Journal of the American Medical Association, vol. 253, no. 7, pp. 1001–1004, 1985. View at Publisher · View at Google Scholar · View at Scopus
  75. R. V. Freeman, M. O'Donnell, D. Share et al., “Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose,” American Journal of Cardiology, vol. 90, no. 10, pp. 1068–1073, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. R. G. Cigarroa, R. A. Lange, R. H. Williams, and L. D. Hillis, “Dosing of contrast material to prevent contrast nephropathy in patients with renal disease,” American Journal of Medicine, vol. 86, no. 6, pp. 649–652, 1989. View at Scopus
  77. P. F. Sherwin, R. Cambron, J. A. Johnson, and J. A. Pierro, “Contrast dose-to-creatinine clearance ratio as a potential indicator of risk for radiocontrast-induced nephropathy: correlation of D/CrCL with area under the contrast concentration-time curve using iodixanol,” Investigative Radiology, vol. 40, no. 9, pp. 598–603, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. U. Nyman, T. Almén, P. Aspelin, M. Hellström, M. Kristiansson, and G. Sterner, “Contrast-medium-induced nephropathy correlated to the ratio between dose in gram iodine and estimated GFR in ml/min,” Acta Radiologica, vol. 46, no. 8, pp. 830–842, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. U. Nyman, J. Björk, P. Aspelin, and G. Marenzi, “Contrast medium dose-to-GFR ratio: a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention,” Acta Radiologica, vol. 49, no. 6, pp. 658–667, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. C. L. Manske, J. M. Sprafka, J. T. Strony, and Y. Wang, “Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography,” American Journal of Medicine, vol. 89, no. 5, pp. 615–620, 1990. View at Publisher · View at Google Scholar · View at Scopus
  81. D. S. Goodman, “Plasma retinol-binding protein,” Annals of the New York Academy of Sciences, vol. 348, pp. 378–390, 1980. View at Scopus
  82. M. Kanai, A. Raz, and D. S. Goodman, “Retinol-binding protein: the transport protein for vitamin A in human plasma,” Journal of Clinical Investigation, vol. 47, no. 9, pp. 2025–2044, 1968. View at Scopus
  83. A. Vahlquist, P. A. Peterson, and L. Wibell, “Metabolism of the viatmin A transporting protein complex. I. Turnover studies in normal persons and in patients with chronic renal failure,” European Journal of Clinical Investigation, vol. 3, no. 4, pp. 352–362, 1973. View at Scopus
  84. L. Scarpioni, P. P. Dall'Aglio, P. G. Poisetti, and C. Buzio, “Retinol binding protein in serum and in urine of glomerular and tubular nephropathies,” Clinica Chimica Acta, vol. 68, no. 2, pp. 107–113, 1976. View at Scopus
  85. A. M. Bernard and R. R. Lauwerys, “Retinol binding protein in urine: a more practical index than urinary β2-microglobulin for the routine screening of renal tubular function,” Clinical Chemistry, vol. 27, no. 10, pp. 1781–1782, 1981. View at Scopus
  86. A. M. Bernard, D. Moreau, and R. Lauwerys, “Comparison of retinol-binding protein and β2-microglobulin determination in urine for the early detection of tubular proteinuria,” Clinica Chimica Acta, vol. 126, no. 1, pp. 1–7, 1982. View at Publisher · View at Google Scholar · View at Scopus
  87. A. M. Bernard, A. A. Vyskocil, P. Mahieu, and R. R. Lauwerys, “Assessment of urinary retinol-binding protein as an index of proximal tubular injury,” Clinical Chemistry, vol. 33, no. 6, pp. 775–779, 1987. View at Scopus
  88. D. S. Roberts, G. B. Haycock, R. N. Dalton et al., “Prediction of acute renal failure after birth asphyxia,” Archives of Disease in Childhood, vol. 65, no. 10, pp. 1021–1028, 1990. View at Scopus
  89. S. R. Walsh, U. Sadat, J. R. Boyle et al., “Remote ischemic preconditioning for renal protection during elective open infrarenal abdominal aortic aneurysm repair: randomized controlled trial,” Vascular and Endovascular Surgery, vol. 44, no. 5, pp. 334–340, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. S. R. Walsh, J. R. Boyle, T. Y. Tang et al., “Remote ischemic preconditioning for renal and cardiac protection during endovascular aneurysm repair: a randomized controlled trial,” Journal of Endovascular Therapy, vol. 16, no. 6, pp. 680–689, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. N. N. Moore, M. Lapsley, A. G. Norden et al., “Does N-acetylcysteine prevent contrast-induced nephropathy during endovascular AAA repair? A randomized controlled pilot study,” Journal of Endovascular Therapy, vol. 13, no. 5, pp. 660–666, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. N. E. Tolkoff-Rubin, R. H. Rubin, and J. V. Bonventre, “Nonivasive renal diagnostic studies,” Clinics in Laboratory Medicine, vol. 8, no. 3, pp. 507–526, 1988. View at Scopus
  93. P. W. Mathieson, “The cellular basis of albuminuria,” Clinical Science, vol. 107, no. 6, pp. 533–538, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. R. D. Toto, “Microalbuminuria: definition, detection, and clinical significance,” Journal of Clinical Hypertension, vol. 6, no. 11, pp. 2–7, 2004. View at Scopus
  95. K. R. Tuttle, “Cardiovascular implications of albuminuria,” Journal of Clinical Hypertension, vol. 6, no. 11, pp. 13–17, 2004. View at Scopus
  96. A. S. Levey, J. Coresh, E. Balk, A. T. Kausz, A. Levin, and M. W. Steffes, “National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” Annals of Internal Medicine, vol. 139, no. 2, pp. 137–147, 2003. View at Scopus
  97. “NICE. Chronic kidney disease- Early identification and management of chronic kidney disease in adults in primary and secondary care,” 2008http://www.nice.org.uk/nicemedia/live/12069/42119/42119.pdf, 2008.
  98. A. Levin, G. E. Pate, S. Shalansky et al., “N-acetylcysteine reduces urinary albumin excretion following contrast administration: evidence of biological effect,” Nephrology Dialysis Transplantation, vol. 22, no. 9, pp. 2520–2524, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. A. J. Barrett, M. E. Davies, and A. Grubb, “The place of human γ-trace (cystatin C) amongst the cysteine proteinase inhibitors,” Biochemical and Biophysical Research Communications, vol. 120, no. 2, pp. 631–636, 1984. View at Scopus
  100. A. O. Grubb, “Cystatin C—Properties and use as diagnostic marker,” Advances in Clinical Chemistry, vol. 35, pp. 63–99, 2001. View at Scopus
  101. V. R. Dharnidharka, C. Kwon, and G. Stevens, “Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis,” American Journal of Kidney Diseases, vol. 40, no. 2, pp. 221–226, 2002. View at Publisher · View at Google Scholar · View at Scopus
  102. E. L. Knight, J. C. Verhave, D. Spiegelman et al., “Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement,” Kidney International, vol. 65, no. 4, pp. 1416–1421, 2004. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Conti, S. Moutereau, M. Zater et al., “Urinary cystatin C as a specific marker of tubular dysfunction,” Clinical Chemistry and Laboratory Medicine, vol. 44, no. 3, pp. 288–291, 2006. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Nejat, J. V. Hill, J. W. Pickering, C. L. Edelstein, P. Devarajan, and Z. H. Endre, “Albuminuria increases cystatin C excretion: implications for urinary biomarkers,” Nephrology Dialysis Transplantation, vol. 27, supplement 3, pp. iii96–ii103, 2012.
  105. Z. Zhang, B. Lu, X. Sheng, and N. Jin, “Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis,” American Journal of Kidney Diseases, vol. 58, no. 3, pp. 356–365, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. L. Kjeldsen, A. H. Johnsen, H. Sengelov, and N. Borregaard, “Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase,” Journal of Biological Chemistry, vol. 268, no. 14, pp. 10425–10432, 1993. View at Scopus
  107. J. B. Cowland and N. Borregaard, “Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans,” Genomics, vol. 45, no. 1, pp. 17–23, 1997. View at Publisher · View at Google Scholar · View at Scopus
  108. T. Betsuyaku, M. Nishimura, K. Takeyabu et al., “Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema,” American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 6, pp. 1985–1991, 1999. View at Scopus
  109. I. Eichler, M. Nilsson, R. Rath, I. Enander, P. Venge, and D. Y. Koller, “Human neutrophil lipocalin, a highly specific marker for acute exacerbation in cystic fibrosis,” European Respiratory Journal, vol. 14, no. 5, pp. 1145–1149, 1999. View at Scopus
  110. J. Bläser, S. Triebel, and H. Tschesche, “A sandwich enzyme immunoassay for the determination of neutrophil lipocalin in body fluids,” Clinica Chimica Acta, vol. 235, no. 2, pp. 137–145, 1995. View at Publisher · View at Google Scholar · View at Scopus
  111. S. Y. Xu, K. Pauksen, and P. Venge, “Serum measurements of human neutrophil lipocalin (HNL) discriminate between acute bacterial and viral infections,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 55, no. 2, pp. 125–131, 1995. View at Scopus
  112. J. Mishra, M. A. Qing, A. Prada et al., “Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury,” Journal of the American Society of Nephrology, vol. 14, no. 10, pp. 2534–2543, 2003. View at Publisher · View at Google Scholar · View at Scopus
  113. J. Mishra, K. Mori, Q. Ma, C. Kelly, J. Barasch, and P. Devarajan, “Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity,” American Journal of Nephrology, vol. 24, no. 3, pp. 307–315, 2004. View at Publisher · View at Google Scholar · View at Scopus
  114. H. Ding, Y. He, K. Li et al., “Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy,” Clinical Immunology, vol. 123, no. 2, pp. 227–234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  115. T. Kuwabara, K. Mori, M. Mukoyama et al., “Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons,” Kidney International, vol. 75, no. 3, pp. 285–294, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. R. Hirsch, C. Dent, H. Pfriem et al., “NGAL is an early predictive biomarker of contrast-induced nephropathy in children,” Pediatric Nephrology, vol. 22, no. 12, pp. 2089–2095, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. J. Mishra, C. Dent, R. Tarabishi et al., “Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery,” The Lancet, vol. 365, no. 9466, pp. 1231–1238, 2005. View at Publisher · View at Google Scholar · View at Scopus
  118. V. Hvidberg, C. Jacobsen, R. K. Strong, J. B. Cowland, S. K. Moestrup, and N. Borregaard, “The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake,” FEBS Letters, vol. 579, no. 3, pp. 773–777, 2005. View at Publisher · View at Google Scholar · View at Scopus
  119. K. Mori, H. T. Lee, D. Rapoport et al., “Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury,” Journal of Clinical Investigation, vol. 115, no. 3, pp. 610–621, 2005. View at Publisher · View at Google Scholar · View at Scopus
  120. K. Makris, D. Rizos, N. Kafkas, and A. Haliassos, “Neurophil gelatinase-associated lipocalin as a new biomarker in laboratory medicine,” Clinical Chemistry and Laboratory Medicine, vol. 50, no. 9, pp. 1519–1532, 2012.
  121. M. Haase, R. Bellomo, P. Devarajan, P. Schlattmann, and A. Haase-Fielitz, “Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis,” American Journal of Kidney Diseases, vol. 54, no. 6, pp. 1012–1024, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. M. Haase, P. Devarajan, A. Haase-Fielitz et al., “The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies,” Journal of the American College of Cardiology, vol. 57, no. 17, pp. 1752–1761, 2011. View at Publisher · View at Google Scholar · View at Scopus
  123. T. L. Nickolas, M. J. O'Rourke, J. Yang et al., “Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury,” Annals of Internal Medicine, vol. 148, no. 11, pp. 810–819, 2008. View at Scopus
  124. T. L. Nickolas, K. M. Schmidt-Ott, P. Canetta et al., “Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study,” Journal of the American College of Cardiology, vol. 59, no. 3, pp. 246–255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  125. H. Bachorzewska-Gajewska, J. Malyszko, E. Sitniewska et al., “Could neutrophil-gelatinase-associated lipocalin and cystatin C predict the development of contrast-induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values?” Kidney and Blood Pressure Research, vol. 30, no. 6, pp. 408–415, 2007. View at Publisher · View at Google Scholar · View at Scopus
  126. G. Wagener, M. Jan, M. Kim et al., “Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery,” Anesthesiology, vol. 105, no. 3, pp. 485–491, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. C. R. Parikh, S. G. Coca, H. Thiessen-Philbrook et al., “Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery,” Journal of the American Society of Nephrology, vol. 22, no. 9, pp. 1748–1757, 2011. View at Publisher · View at Google Scholar · View at Scopus
  128. L. Cai, J. Rubin, W. Han, P. Venge, and S. Xu, “The origin of multiple molecular forms in urine of HNL/NGAL,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 12, pp. 2229–2235, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. S. Y. Xu, C. G. B. Petersson, M. Carlson, and P. Venge, “The development of an assay for human neutrophil lipocalin (HNL)-to be used as a specific marker of neutrophil activity in vivo and vitro,” Journal of Immunological Methods, vol. 171, no. 2, pp. 245–252, 1994. View at Publisher · View at Google Scholar · View at Scopus
  130. S. Hatipoglu, E. Sevketoglu, A. Gedikbasi et al., “Urinary MMP-9/NGAL complex in children with acute cystitis,” Pediatric Nephrology, vol. 26, no. 8, pp. 1263–1268, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. T. L. Nickolas, C. S. Forster, M. E. Sise, et al., “NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease,” Kidney International, vol. 82, no. 6, pp. 718–722, 2012. View at Publisher · View at Google Scholar
  132. H. Park, J. Seo, and S. Lee, “The Relationship between serum neutrophil gelatinase-associated lipocalin and renal function in patients with vancomycin treatment,” Annals of Clinical and Laboratory Science, vol. 42, no. 1, pp. 7–13, 2012. View at Scopus
  133. G. Lippi, G. L. Salvagno, and G. Banfi, “Serum but not urine concentration of neutrophil gelatinase-associated lipocalin is influenced by acute leukocyte variations,” Leukemia & Lymphoma, vol. 53, no. 8, pp. 1643–1645, 2012.
  134. Y. Tomonaga, T. Szucs, P. Ambühl, S. Nock, M. Risch, and L. Risch, “Insights on urinary NGAL obtained in a primary care setting,” Clinica Chimica Acta, vol. 413, no. 7-8, pp. 733–739, 2012. View at Publisher · View at Google Scholar · View at Scopus
  135. S. T. Cochran, W. S. Wong, and D. J. Roe, “Predicting angiography- induced acute renal function impairment: clinical risk model,” American Journal of Roentgenology, vol. 141, no. 5, pp. 1027–1033, 1983. View at Scopus
  136. R. D. Swartz, J. E. Rubin, P. Leeming, and P. Silva, “Renal failure following major angiography,” American Journal of Medicine, vol. 65, no. 1, pp. 31–37, 1978. View at Scopus
  137. E. M. Lautin, N. J. Freeman, A. H. Schoenfeld et al., “Radiocontrast-associated renal dysfunction: incidence and risk factors,” American Journal of Roentgenology, vol. 157, no. 1, pp. 49–58, 1991. View at Scopus
  138. M. J. E. Gussenhoven, J. Ravensbergen, J. H. Van Bockel, J. D. M. Feuth, and J. C. N. M. Aarts, “Renal dysfunction after angiography; a risk factor analysis in patients with peripheral vascular disease,” Journal of Cardiovascular Surgery, vol. 32, no. 1, pp. 81–86, 1991. View at Scopus
  139. R. Mehran, E. D. Aymong, E. Nikolsky et al., “A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation,” Journal of the American College of Cardiology, vol. 44, no. 7, pp. 1393–1399, 2004. View at Publisher · View at Google Scholar · View at Scopus
  140. B. A. Bartholomew, K. J. Harjai, S. Dukkipati et al., “Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification,” American Journal of Cardiology, vol. 93, no. 12, pp. 1515–1519, 2004. View at Publisher · View at Google Scholar · View at Scopus
  141. G. Marenzi, G. Lauri, E. Assanelli et al., “Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction,” Journal of the American College of Cardiology, vol. 44, no. 9, pp. 1780–1785, 2004. View at Publisher · View at Google Scholar · View at Scopus
  142. J. R. Brown, J. T. DeVries, W. D. Piper et al., “Serious renal dysfunction after percutaneous coronary interventions can be predicted,” American Heart Journal, vol. 155, no. 2, pp. 260–266, 2008. View at Publisher · View at Google Scholar · View at Scopus
  143. D. Tziakas, G. Chalikias, D. Stakos et al., “Development of an easily applicable risk score model for contrast-induced nephropathy prediction after percutaneous coronary intervention. A novel approach tailored to current practice,” International Journal of Cardiology, 2011. View at Publisher · View at Google Scholar · View at Scopus
  144. E. Chong, L. Shen, K. K. Poh, and H. C. Tan, “Risk scoring system for prediction of contrastinduced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention,” Singapore Medical Journal, vol. 53, no. 3, pp. 164–169, 2012. View at Scopus
  145. N. Fu, X. Li, S. Yang, et al., “Risk score for the prediction of contrast-induced nephropathy in elderly patients undergoing percutaneous coronary intervention,” Angiology, vol. 64, no. 3, pp. 188–194, 2013.
  146. H. S. Gurm, M. Seth, J. Kooiman, and D. Share, “A novel tool for reliable and accurate prediction of renal complications in patients undergoing percutaneous coronary intervention,” Journal of the American College of Cardiology, vol. 61, no. 22, pp. 2242–2248, 2013.
  147. R. G. Grainger, “Renal toxicity of radiological contrast media,” British Medical Bulletin, vol. 28, no. 3, pp. 191–195, 1972. View at Scopus
  148. A. J. Davidson, J. Becker, N. Rothfield, G. Unger, and D. R. Ploch, “An evaluation of the effect of high-dose urography on previously impaired renal and hepatic function in man,” Radiology, vol. 97, no. 2, pp. 249–254, 1970. View at Scopus
  149. G. H. Myers Jr. and D. M. Witten, “Acute renal failure after excretory urography in multiple myeloma,” The American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine, vol. 113, no. 3, pp. 583–588, 1971. View at Scopus
  150. P. J. Dudzinski, A. F. Petrone, M. Persoff, and E. E. Callaghan, “Acute renal failure following high dose excretory urography in dehydrated patients,” Journal of Urology, vol. 106, no. 5, pp. 619–621, 1971. View at Scopus
  151. W. E. Berdon, D. H. Baker, and J. A. Becker, “Danger of dehydration in pyelography,” New England Journal of Medicine, vol. 281, no. 3, pp. 167–168, 1969. View at Scopus
  152. H. R. Anto, S.-Y. Chou, J. G. Porush, and W. B. Shapiro, “Infusion intravenous pyelography and renal function. Effects of hypertonic mannitol in patients with chronic renal insufficiency,” Archives of Internal Medicine, vol. 141, no. 12, pp. 1652–1656, 1981. View at Publisher · View at Google Scholar · View at Scopus
  153. R. L. Eisenberg, W. O. Bank, and M. W. Hedgock, “Renal failure after major angiography can be avoided with hydration,” American Journal of Roentgenology, vol. 136, no. 5, pp. 859–861, 1981. View at Scopus
  154. M. D. Kerstein and F. A. Puyau, “Value of periangiography hydration,” Surgery, vol. 96, no. 5, pp. 919–922, 1984. View at Scopus
  155. R. Solomon, C. Werner, D. Mann, J. D'Elia, and P. Silva, “Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents,” New England Journal of Medicine, vol. 331, no. 21, pp. 1416–1420, 1994. View at Publisher · View at Google Scholar · View at Scopus
  156. H. S. Trivedi, H. Moore, S. Nasr et al., “A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity,” Nephron. Clinical practice, vol. 93, no. 1, pp. C29–34, 2003. View at Scopus
  157. B. D. Bader, E. D. Berger, M. B. Heede et al., “What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?” Clinical Nephrology, vol. 62, no. 1, pp. 1–7, 2004. View at Scopus
  158. W. A. Pryor and G. L. Squadrito, “The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide,” American Journal of Physiology, vol. 268, no. 5, pp. L699–L722, 1995. View at Scopus
  159. Y. Agmon, H. Peleg, Z. Greenfeld, S. Rosen, and M. Brezis, “Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat,” Journal of Clinical Investigation, vol. 94, no. 3, pp. 1069–1075, 1994. View at Scopus
  160. A. J. Taylor, D. Hotchkiss, R. W. Morse, and J. McCabe, “PREPARED: preparation for angiography in renal dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction,” Chest, vol. 114, no. 6, pp. 1570–1574, 1998. View at Scopus
  161. B. Dussol, S. Morange, A. Loundoun, P. Auquier, and Y. Berland, “A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients,” Nephrology Dialysis Transplantation, vol. 21, no. 8, pp. 2120–2126, 2006. View at Publisher · View at Google Scholar · View at Scopus
  162. W. Wróbel, W. Sinkiewicz, M. Gordon, and A. Woźniak-Wiśniewska, “Oral versus intravenous hydration and renal function in diabetic patients undergoing percutaneous coronary interventions,” Kardiologia Polska, vol. 68, no. 9, pp. 1015–1020, 2010. View at Scopus
  163. R. J. Alpern, Renal Acidification Mechanisms, WB Saunders, Philadelphia, Pa, USA, 6th edition, 2000.
  164. B. Halliwell and J. M. C. Gutteridge, “Role of free radicals and catalytic metal ions in human disease: an overview,” Methods in Enzymology, vol. 186, pp. 1–85, 1990. View at Publisher · View at Google Scholar · View at Scopus
  165. G. Cohen, The Fenton Reaction, CRC Press, Boca Raton, Fla, USA, 1985.
  166. M. I. Lindinger, T. W. Franklin, L. C. Lands, P. K. Pedersen, D. G. Welsh, and G. J. F. Heigenhauser, “NaHCO3 and KHCO3 ingestion rapidly increases renal electrolyte excretion in humans,” Journal of Applied Physiology, vol. 88, no. 2, pp. 540–550, 2000. View at Scopus
  167. G. J. Merten, W. P. Burgess, L. V. Gray et al., “Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial,” Journal of the American Medical Association, vol. 291, no. 19, pp. 2328–2334, 2004. View at Publisher · View at Google Scholar · View at Scopus
  168. J. L. Teruel, R. Marcen, J. A. Herrero, C. Felipe, and J. Ortuño, “An easy and effective procedure to prevent radiocontrast agent nephrotoxicity in high-risk patients,” Nephron, vol. 51, no. 2, p. 282, 1989. View at Scopus
  169. M. Brezis and S. Rosen, “Mechanisms of disease: hypoxia of the renal medulla-its implications for disease,” New England Journal of Medicine, vol. 332, no. 10, pp. 647–655, 1995. View at Publisher · View at Google Scholar · View at Scopus
  170. J. L. Caulfield, S. P. Singh, J. S. Wishnok, W. M. Deen, and S. R. Tannenbaum, “Bicarbonate inhibits N-nitrosation in oxygenated nitric oxide solutions,” Journal of Biological Chemistry, vol. 271, no. 42, pp. 25859–25863, 1996. View at Publisher · View at Google Scholar · View at Scopus
  171. F. Assadi, “Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug,” Pediatric Cardiology, vol. 27, no. 2, pp. 238–242, 2006. View at Publisher · View at Google Scholar · View at Scopus
  172. A. Tamura, Y. Goto, K. Miyamoto et al., “Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure,” American Journal of Cardiology, vol. 104, no. 7, pp. 921–925, 2009. View at Publisher · View at Google Scholar · View at Scopus
  173. C. Briguori, F. Airoldi, D. D'Andrea et al., “Renal insufficiency following contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategies,” Circulation, vol. 115, no. 10, pp. 1211–1217, 2007. View at Publisher · View at Google Scholar · View at Scopus
  174. M. Lin, M. Sabeti, E. Iskander, N. Malhotra, and P. Pham, “Prevention of contrast nephropathy with sodium bicarbonate,” in Proceedings of the American Society of Nephrology Meeting (abstract SA-PO2986), Pennsylvania, Pa, USA, 2008.
  175. A. Recio-Mayoral, M. Chaparro, B. Prado et al., “The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention. The RENO study,” Journal of the American College of Cardiology, vol. 49, no. 12, pp. 1283–1288, 2007. View at Publisher · View at Google Scholar · View at Scopus
  176. M. Masuda, T. Yamada, T. Mine et al., “Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure,” American Journal of Cardiology, vol. 100, no. 5, pp. 781–786, 2007. View at Publisher · View at Google Scholar · View at Scopus
  177. S. E. Hogan, P. L'Allier, S. Chetcuti et al., “Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis,” American Heart Journal, vol. 156, no. 3, pp. 414–421, 2008. View at Publisher · View at Google Scholar · View at Scopus
  178. S. D. Navaneethan, S. Singh, S. Appasamy, R. E. Wing, and A. R. Sehgal, “Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis,” American Journal of Kidney Diseases, vol. 53, no. 4, pp. 617–627, 2009. View at Publisher · View at Google Scholar · View at Scopus
  179. S. Zoungas, T. Ninomiya, R. Huxley et al., “Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy,” Annals of Internal Medicine, vol. 151, no. 9, pp. 631–638, 2009. View at Publisher · View at Google Scholar · View at Scopus
  180. S. S. Brar, S. Hiremath, G. Dangas, R. Mehran, S. K. Brar, and M. B. Leon, “Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 10, pp. 1584–1592, 2009. View at Publisher · View at Google Scholar · View at Scopus
  181. E. A. J. Hoste, J. J. De Waele, S. A. Gevaert, S. Uchino, and J. A. Kellum, “Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis,” Nephrology Dialysis Transplantation, vol. 25, no. 3, pp. 747–758, 2010. View at Publisher · View at Google Scholar · View at Scopus
  182. J. S. Jang, H. Y. Jin, J. S. Seo, et al., “Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury-a systematic review and meta-analysis,” Circulation Journal, vol. 76, no. 9, pp. 2255–2265.
  183. P. Meier, D. T. Ko, A. Tamura, U. Tamhane, and H. S. Gurm, “Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis,” BMC Medicine, vol. 7, p. 23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  184. A. Tamura, Y. Goto, K. Miyamoto et al., “Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure,” American Journal of Cardiology, vol. 104, no. 7, pp. 921–925, 2009. View at Publisher · View at Google Scholar · View at Scopus
  185. P. P. Meier and H. S. Gurm, “Is simpler also better? Brief sodium bicarbonate infusion to prevent contrast-induced nephropathy,” American Journal of Cardiology, vol. 105, no. 7, pp. 1042–1043, 2010. View at Publisher · View at Google Scholar · View at Scopus
  186. O. Berwanger, “Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized acetylcysteine for contrast-induced nephropathy trial (ACT),” Circulation, vol. 124, no. 11, pp. 1250–1259, 2011. View at Publisher · View at Google Scholar · View at Scopus
  187. Y. Li, Y. Liu, L. Fu, C. Mei, and B. Dai, “Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials,” PLoS ONE, vol. 7, no. 4, Article ID e34450, 2013.
  188. U. Sadat, “Contrast-induced nephropathy: do statins offer protection?” Current Opinion in Cardiology, vol. 26, no. 4, pp. 334–337, 2011. View at Publisher · View at Google Scholar · View at Scopus
  189. K. Spargias, E. Alexopoulos, S. Kyrzopoulos et al., “Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention,” Circulation, vol. 110, no. 18, pp. 2837–2842, 2004. View at Publisher · View at Google Scholar · View at Scopus
  190. A. Boscheri, C. Weinbrenner, B. Botzek, K. Reynen, E. Kuhlisch, and R. H. Strasser, “Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction,” Clinical Nephrology, vol. 68, no. 5, pp. 279–286, 2007. View at Scopus
  191. S. Jo, B. Koo, J. Park et al., “N-acetylcysteine versus AScorbic acid for Preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography. NASPI study—a prospective randomized controlled trial,” American Heart Journal, vol. 157, no. 3, pp. 576–583, 2009. View at Publisher · View at Google Scholar · View at Scopus
  192. M. Brueck, H. Cengiz, and A. Boening, “N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization: a single center, prospective, double-blind, placebo-controlled, randomized trial,” Journal of the American College of Cardiology, vol. 57, no. 14, supplement s1, p. E595, 2011.
  193. L. Zhou and H. Chen, “Prevention of contrast-induced nephropathy with ascorbic acid,” Internal Medicine, vol. 51, no. 6, pp. 531–535, 2012. View at Publisher · View at Google Scholar · View at Scopus
  194. M. A. Albabtain, A. Almasood, H. Alshurafah, H. Alamri, and H. Tamim, “Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-Induced nephropathy: a prospective randomized study,” Journal of Interventional Cardiology, vol. 26, no. 1, pp. 90–96, 2013.
  195. B. Dai, Y. Liu, L. Fu, Y. Li, J. Zhang, and C. Mei, “Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials,” American Journal of Kidney Diseases, 2012. View at Publisher · View at Google Scholar · View at Scopus
  196. M. Zafarullah, W. Q. Li, J. Sylvester, and M. Ahmad, “Molecular mechanisms of N-acetylcysteine actions,” Cellular and Molecular Life Sciences, vol. 60, no. 1, pp. 6–20, 2003. View at Publisher · View at Google Scholar · View at Scopus
  197. O. I. Aruoma, B. Halliwell, B. M. Hoey, and J. Butler, “The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid,” Free Radical Biology and Medicine, vol. 6, no. 6, pp. 593–597, 1989. View at Scopus
  198. E. Skrzydlewska and R. Farbiszewski, “Protective effect of N-acetylcysteine on reduced glutathione, reduced glutathione-related enzymes and lipid peroxidation in methanol intoxication,” Drug and Alcohol Dependence, vol. 57, no. 1, pp. 61–67, 1999. View at Publisher · View at Google Scholar · View at Scopus
  199. H. Nakano, K. Boudjema, E. Alexandre et al., “Protective effects of N-acetylcysteine on hypothermic ischemia-reperfusion injury of rat liver,” Hepatology, vol. 22, no. 2, pp. 539–545, 1995. View at Scopus
  200. N. Nitescu, S. Ricksten, N. Marcussen et al., “N-acetylcysteine attenuates kidney injury in rats subjected to renal ischaemia-reperfusion,” Nephrology Dialysis Transplantation, vol. 21, no. 5, pp. 1240–1247, 2006. View at Publisher · View at Google Scholar · View at Scopus
  201. K. Dobashi, I. Singh, J. K. Orak, K. Asayama, and A. K. Singh, “Combination therapy of N-acetylcysteine, sodium nitroprusside and phosphoramidon attenuates ischemia-reperfusion injury in rat kidney,” Molecular and Cellular Biochemistry, vol. 240, no. 1-2, pp. 9–17, 2002. View at Publisher · View at Google Scholar · View at Scopus
  202. A. Ahmad, S. Mondello, R. Di Paola et al., “Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine,” European Journal of Pharmacology, vol. 674, no. 2-3, pp. 397–406, 2012. View at Publisher · View at Google Scholar · View at Scopus
  203. T. Saitoh, H. Satoh, M. Nobuhara et al., “Intravenous glutathione prevents renal oxidative stress after coronary angiography more effectively than oral N-acetylcysteine,” Heart and Vessels, vol. 26, no. 5, pp. 465–472, 2011. View at Scopus
  204. E. L. Conesa, F. Valero, J. C. Nadal et al., “N-acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure,” American Journal of Physiology, vol. 281, no. 3, pp. R730–R737, 2001. View at Scopus
  205. J. Loscalzo, “N-acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin,” Journal of Clinical Investigation, vol. 76, no. 2, pp. 703–708, 1985. View at Scopus
  206. M. G. Salom, P. Ramírez, L. F. Carbonell et al., “Protective effect of N-acetyl-L-cysteine on the renal failure induced by inferior vena cava occlusion,” Transplantation, vol. 65, no. 10, pp. 1315–1321, 1998. View at Publisher · View at Google Scholar · View at Scopus
  207. H. Girouard, C. Chulak, L. Wu, M. Lejossec, and J. De Champlain, “N-acetylcysteine improves nitric oxide and α-adrenergic pathways in mesenteric beds of spontaneously hypertensive rats,” American Journal of Hypertension, vol. 16, no. 7, pp. 577–584, 2003. View at Publisher · View at Google Scholar · View at Scopus
  208. S. Efrati, S. Berman, I. Ilgiyeav, Y. Siman-Tov, Z. Averbukh, and J. Weissgarten, “Differential effects of N-acetylcysteine, theophylline or bicarbonate on contrast-induced rat renal vasoconstriction,” American Journal of Nephrology, vol. 29, no. 3, pp. 181–191, 2009. View at Publisher · View at Google Scholar · View at Scopus
  209. S. Efrati, S. Berman, Y. Siman-Tov et al., “N-acetylcysteine attenuates NSAID-induced rat renal failure by restoring intrarenal prostaglandin synthesis,” Nephrology Dialysis Transplantation, vol. 22, no. 7, pp. 1873–1881, 2007. View at Publisher · View at Google Scholar · View at Scopus
  210. S. N. Heyman, M. Goldfarb, A. Shina, F. Karmeli, and S. Rosen, “N-acetylcysteine ameliorates renal microcirculation: studies in rats,” Kidney International, vol. 63, no. 2, pp. 634–641, 2003. View at Publisher · View at Google Scholar · View at Scopus
  211. A. M. Kelly, B. Dwamena, P. Cronin, S. J. Bernstein, and R. C. Carlos, “Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy,” Annals of Internal Medicine, vol. 148, no. 4, pp. 284–294, 2008. View at Scopus
  212. R. Birck, S. Krzossok, F. Markowetz, P. Schnülle, F. J. Van Der Woude, and C. Braun, “Acetylcysteine for prevention of contrast nephropathy: meta-analysis,” The Lancet, vol. 362, no. 9384, pp. 598–603, 2003. View at Publisher · View at Google Scholar · View at Scopus
  213. D. W. Isenbarger, S. M. Kent, and P. G. O'Malley, “Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy,” American Journal of Cardiology, vol. 92, no. 12, pp. 1454–1458, 2003. View at Publisher · View at Google Scholar · View at Scopus
  214. A. Alonso, J. Lau, B. L. Jaber, A. Weintraub, and M. J. Sarnak, “Prevention of radiocontrast nephropathy with N-Acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials,” American Journal of Kidney Diseases, vol. 43, no. 1, pp. 1–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  215. N. Pannu, B. Manns, H. Lee, and M. Tonelli, “Systematic review of the impact of N-acetylcysteine on contrast nephropathy,” Kidney International, vol. 65, no. 4, pp. 1366–1374, 2004. View at Publisher · View at Google Scholar · View at Scopus
  216. V. Guru and S. E. Fremes, “The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy,” Clinical Nephrology, vol. 62, no. 2, pp. 77–83, 2004. View at Scopus
  217. S. M. Bagshaw and W. A. Ghali, “Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic reveiw and meta-analysis,” BMC Medicine, vol. 2, p. 38, 2004. View at Publisher · View at Google Scholar · View at Scopus
  218. B. K. Nallamothu, K. G. Shojania, S. Saint et al., “Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis,” American Journal of Medicine, vol. 117, no. 12, pp. 938–947, 2004. View at Publisher · View at Google Scholar · View at Scopus
  219. M. H. Duong, T. A. MacKenzie, and D. J. Malenka, “N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis,” Catheterization and Cardiovascular Interventions, vol. 64, no. 4, pp. 471–479, 2005. View at Publisher · View at Google Scholar · View at Scopus
  220. I. Goldenberg, M. Shechter, S. Matetzky et al., “Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: a randomized controlled trial and review of the current literature,” European Heart Journal, vol. 25, no. 3, pp. 212–218, 2004. View at Publisher · View at Google Scholar · View at Scopus
  221. D. Misra, K. Leibowtiz, R. M. Gowda, M. Shapiro, and I. A. Khan, “Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis,” Clinical Cardiology, vol. 27, no. 11, pp. 607–610, 2004. View at Scopus
  222. R. Liu, D. Nair, J. Ix, D. H. Moore, and S. Bent, “N-acetylcysteine for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis,” Journal of General Internal Medicine, vol. 20, no. 2, pp. 193–200, 2005. View at Publisher · View at Google Scholar · View at Scopus
  223. A. Zagler, M. Azadpour, C. Mercado, and C. H. Hennekens, “N-Acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials,” American Heart Journal, vol. 151, no. 1, pp. 140–145, 2006. View at Publisher · View at Google Scholar · View at Scopus
  224. D. A. Gonzales, K. J. Norsworthy, S. J. Kern et al., “A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity,” BMC Medicine, vol. 5, p. 32, 2007. View at Publisher · View at Google Scholar · View at Scopus
  225. H. Trivedi, S. Daram, A. Szabo, A. L. Bartorelli, and G. Marenzi, “High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy,” American Journal of Medicine, vol. 122, no. 9, pp. 874–e9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  226. S. O'Sullivan, D. A. Healy, M. C. Moloney, P. A. Grace, and S. R. Walsh, “The role of N-acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis,” Angiology, 2012.
  227. Z. Sun, Q. Fu, L. Cao, W. Jin, L. Cheng, and Z. Li, “Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials,” PLoS ONE, vol. 8, no. 1, Article ID e55124, 2013.
  228. U. Hoffmann, M. Fischereder, B. Krüger, W. Drobnik, and B. K. Krämer, “The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable,” Journal of the American Society of Nephrology, vol. 15, no. 2, pp. 407–410, 2004. View at Publisher · View at Google Scholar · View at Scopus
  229. E. Macedo, R. Abdulkader, I. Castro, A. C. C. Sobrinho, L. Yu, and J. M. Vieira Jr., “Lack of protection of N-acetylcysteine (NAC) in acute renal failure related to elective aortic aneurysm repair—a randomized controlled trial,” Nephrology Dialysis Transplantation, vol. 21, no. 7, pp. 1863–1869, 2006. View at Publisher · View at Google Scholar · View at Scopus
  230. P. T. Vaitkus and C. Brar, “N-Acetylcysteine in the prevention of contrast-induced nephropathy: publication bias perpetuated by meta-analyses,” American Heart Journal, vol. 153, no. 2, pp. 275–280, 2007. View at Publisher · View at Google Scholar · View at Scopus
  231. “ACT-Trial-Investigators Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy,” Trials, vol. 10, p. 38, 2009.
  232. I. D. Podmore, H. R. Griffiths, K. E. Herbert, N. Mistry, P. Mistry, and J. Lunec, “Vitamin C exhibits pro-oxidant properties,” Nature, vol. 392, no. 6676, p. 559, 1998. View at Publisher · View at Google Scholar · View at Scopus
  233. G. R. Buettner and B. A. Jurkiewicz, “Catalytic metals, ascorbate and free radicals: combinations to avoid,” Radiation Research, vol. 145, no. 5, pp. 532–541, 1996. View at Publisher · View at Google Scholar · View at Scopus
  234. J. Du, J. J. Cullen, and G. R. Buettner, “Ascorbic acid: chemistry, biology and the treatment of cancer,” Biochim Biophys Acta, vol. 1826, no. 2, pp. 443–457, 2012.
  235. S. J. Padayatty, H. Sun, Y. Wang et al., “Vitamin C pharmacokinetics: implications for oral and intravenous use,” Annals of Internal Medicine, vol. 140, no. 7, pp. 533–I61, 2004. View at Scopus
  236. B. H. J. Bielski, H. W. Richter, and P. C. Chan, “Some properties of the ascorbate free radical,” Annals of the New York Academy of Sciences, vol. 258, pp. 231–237, 1975. View at Scopus
  237. G. N. Levine, B. Frei, S. N. Koulouris, M. D. Gerhard, J. F. Keaney Jr., and J. A. Vita, “Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease,” Circulation, vol. 93, no. 6, pp. 1107–1113, 1996. View at Scopus
  238. T. Motoyama, H. Kawano, K. Kugiyama et al., “Endothelium-dependent vasodilation in the brachial artery is impaired in smokers: effect of vitamin C,” American Journal of Physiology, vol. 273, no. 4, pp. H1644–H1650, 1997. View at Scopus
  239. S. J. Duffy, N. Gokce, M. Holbrook et al., “Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension,” American Journal of Physiology, vol. 280, no. 2, pp. H528–H534, 2001. View at Scopus
  240. A. Boscheri, C. Weinbrenner, B. Botzek, K. Reynen, E. Kuhlisch, and R. H. Strasser, “Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction,” Clinical Nephrology, vol. 68, no. 5, pp. 279–286, 2007. View at Scopus
  241. S. Jo, B. Koo, J. Park et al., “N-acetylcysteine versus AScorbic acid for Preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography. NASPI study-a prospective randomized controlled trial,” American Heart Journal, vol. 157, no. 3, pp. 576–583, 2009. View at Publisher · View at Google Scholar · View at Scopus
  242. L. Zhou and H. Chen, “Prevention of contrast-induced nephropathy with ascorbic acid,” Internal Medicine, vol. 51, no. 6, pp. 531–535, 2012. View at Publisher · View at Google Scholar · View at Scopus
  243. K. Komiyama, T. Tejima, Y. Tanab, and H. Sakurada, “Is ascorbic acid effective in preventing contrast-induced acute kidney injury?” American Journal of Cardiology, vol. 105, no. 9, supplement 1, 2011.
  244. L. Zhou and H. Chen, “Prevention of contrast-induced nephropathy with ascorbic acid,” Internal Medicine, vol. 51, no. 6, pp. 531–535, 2012. View at Publisher · View at Google Scholar · View at Scopus
  245. M. A. Albabtain, A. Almasood, H. Alshurafah, H. Alamri, and H. Tamim, “Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-induced nephropathy: a prospective randomized study,” Journal of Interventional Cardiology, vol. 26, no. 1, pp. 90–96, 2013.
  246. S. Hamdi, W. Selmi, A. Hraiech, W. Jomaa, K. B. Hamda, and F. Maatouk, “Prevention of contrast induced nephropathy in patients undergoing coronarography with ascorbic acid,” JACC: Cardiovascular Interventions, vol. 6, no. 2, supplement 1, p. S22, 2013.
  247. U. Sadat, A. Usman, J. H. Gillard, and J. R. Boyle, “Does ascorbic acid protect against contrast induced-acute kidney injury in patients undergoing coronary angiography—a systematic review with meta-analysis of randomized controlled trials,” Journal of the American College of Cardiology, 2013. View at Publisher · View at Google Scholar
  248. S. John, M. P. Schneider, C. Delles, J. Jacobi, and R. E. Schmieder, “Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients,” American Heart Journal, vol. 149, no. 3, pp. 473–e1, 2005. View at Publisher · View at Google Scholar · View at Scopus
  249. U. Laufs and J. K. Liao, “Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase,” Journal of Biological Chemistry, vol. 273, no. 37, pp. 24266–24271, 1998. View at Publisher · View at Google Scholar · View at Scopus
  250. W. H. Kaesemeyer, R. B. Caldwell, J. Huang, and R. William Caldwell, “Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions,” Journal of the American College of Cardiology, vol. 33, no. 1, pp. 234–241, 1999. View at Publisher · View at Google Scholar · View at Scopus
  251. P. M. Ridker, N. Rifai, M. Clearfield et al., “Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events,” New England Journal of Medicine, vol. 344, no. 26, pp. 1959–1965, 2001. View at Publisher · View at Google Scholar · View at Scopus
  252. A. H. Wagner, T. Köhler, U. Rückschloss, I. Just, and M. Hecker, “Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 1, pp. 61–69, 2000. View at Scopus
  253. K. E. Al-Otaibi, A. M. Al Elaiwi, M. Tariq, and A. K. Al-Asmari, “Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase, and nitric oxide,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 831748, 8 pages, 2012. View at Publisher · View at Google Scholar
  254. P. O. Bonetti, L. O. Lerman, C. Napoli, and A. Lerman, “Statin effects beyond lipid lowering—are they clinically relevant?” European Heart Journal, vol. 24, no. 3, pp. 225–248, 2003. View at Publisher · View at Google Scholar · View at Scopus
  255. S. Jo, B. Koo, J. Park et al., “Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study,” American Heart Journal, vol. 155, no. 3, pp. 499–e1, 2008. View at Publisher · View at Google Scholar · View at Scopus
  256. J. Xinwei, F. Xianghua, Z. Jing et al., “Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention,” American Journal of Cardiology, vol. 104, no. 4, pp. 519–524, 2009. View at Publisher · View at Google Scholar · View at Scopus
  257. X. Zhou, Y. Jin, Q. Wang, R. Min, and X. Zhang, “Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography,” Zhonghua Xin Xue Guan Bing Za Zhi, vol. 37, no. 5, pp. 394–396, 2009. View at Scopus
  258. H. Özhan, I. Erden, S. Ordu et al., “Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography,” Angiology, vol. 61, no. 7, pp. 711–714, 2010. View at Publisher · View at Google Scholar · View at Scopus
  259. A. Toso, M. Maioli, M. Leoncini et al., “Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease,” American Journal of Cardiology, vol. 105, no. 3, pp. 288–292, 2010. View at Publisher · View at Google Scholar · View at Scopus
  260. S. Acikel, H. Muderrisoglu, A. Yildirir et al., “Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography,” Blood Coagulation and Fibrinolysis, vol. 21, no. 8, pp. 750–757, 2010. View at Publisher · View at Google Scholar · View at Scopus
  261. G. Patti, E. Ricottini, A. Nusca et al., “Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial,” American Journal of Cardiology, vol. 108, no. 1, pp. 1–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  262. Y. Li, Y. Liu, L. Fu, C. Mei, and B. Dai, “Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials,” PLoS ONE, vol. 7, no. 4, Article ID e34450, 2012.
  263. H. Osswald, “Renal effects of adenosine and their inhibition by theophylline in dogs,” NAUNYN.SCHMIED.ARCH.PHARM., vol. 288, no. 1, pp. 79–86, 1975. View at Scopus
  264. L. J. Arend, C. I. Thompson, and W. S. Spielman, “Dipyridamole decreases glomerular filtration in the sodium-depleted dog. Evidence for mediation by intrarenal adenosine,” Circulation Research, vol. 56, no. 2, pp. 242–251, 1985. View at Scopus
  265. L. J. Arend, G. L. Bakris, J. C. Burnett Jr., C. Megerian, and W. S. Spielman, “Role for intrarenal adenosine in the renal hemodynamic response to contrast media,” Journal of Laboratory and Clinical Medicine, vol. 110, no. 4, pp. 406–411, 1987. View at Scopus
  266. C. M. Erley, S. H. Duda, S. Schlepckow et al., “Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application,” Kidney International, vol. 45, no. 5, pp. 1425–1431, 1994. View at Scopus
  267. C. M. Erley, N. Heyne, K. Burgert, J. Langanke, T. Risler, and H. Osswald, “Prevention of radiocontrast-induced nephropathy by adenosine antagonists in rats with chronic nitric oxide deficiency,” Journal of the American Society of Nephrology, vol. 8, no. 7, pp. 1125–1132, 1997. View at Scopus
  268. M. R. Gandhi, P. Brown, C. A. Romanowski et al., “The use of theophylline, an adenosine antagonist in the prevention of contrast media induced nephrotoxicity,” British Journal of Radiology, vol. 65, no. 777, p. 838, 1992. View at Scopus
  269. R. E. Katholi, G. J. Taylor, W. P. McCann et al., “Nephrotoxicity from contrast media: attenuation with theophylline,” Radiology, vol. 195, no. 1, pp. 17–22, 1995. View at Scopus
  270. A. Kolonko, A. Wiecek, and F. Kokot, “The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents,” Journal of Nephrology, vol. 11, no. 3, pp. 151–156, 1998. View at Scopus
  271. A. S. Abizaid, C. E. Clark, G. S. Mintz et al., “Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency,” American Journal of Cardiology, vol. 83, no. 2, pp. 260–263, 1999. View at Publisher · View at Google Scholar · View at Scopus
  272. C. M. Erley, S. H. Duda, D. Rehfuss et al., “Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline,” Nephrology Dialysis Transplantation, vol. 14, no. 5, pp. 1146–1149, 1999. View at Publisher · View at Google Scholar · View at Scopus
  273. W. Huber, K. Ilgmann, M. Page et al., “Effect of theophylline on contrast material-induced nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study,” Radiology, vol. 223, no. 3, pp. 772–779, 2002. View at Scopus
  274. A. Kapoor, S. Kumar, S. Gulati, S. Gambhir, R. S. Sethi, and N. Sinha, “The role of theophylline in contrast-induced nephropathy: a case-control study,” Nephrology Dialysis Transplantation, vol. 17, no. 11, pp. 1936–1941, 2002. View at Scopus
  275. W. Huber, C. Schipek, K. Ilgmann et al., “Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency,” American Journal of Cardiology, vol. 91, no. 10, pp. 1157–1162, 2003. View at Publisher · View at Google Scholar · View at Scopus
  276. W. Huber, F. Eckel, M. Hennig et al., “Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study,” Radiology, vol. 239, no. 3, pp. 793–804, 2006. View at Publisher · View at Google Scholar · View at Scopus
  277. M. Baskurt, B. Okcun, O. Abaci et al., “N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy,” European Journal of Clinical Investigation, vol. 39, no. 9, pp. 793–799, 2009. View at Publisher · View at Google Scholar · View at Scopus
  278. J. Matejka, I. Varvarovsky, P. Vojtisek et al., “Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease,” Heart and Vessels, vol. 25, no. 6, pp. 536–542, 2010. View at Publisher · View at Google Scholar · View at Scopus
  279. T. Kinbara, T. Hayano, N. Ohtani, Y. Furutani, K. Moritani, and M. Matsuzaki, “Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy,” Journal of Cardiology, vol. 55, no. 2, pp. 174–179, 2010. View at Publisher · View at Google Scholar · View at Scopus
  280. M. Malhis, S. Al-Bitar, and K. Al-Deen Zaiat, “The role of theophylline in prevention of radiocontrast media-induced nephropathy,” Saudi Journal of Kidney Diseases and Transplantation, vol. 21, no. 2, pp. 276–283, 2010. View at Scopus
  281. A. Rohani, “Effectiveness of aminophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency,” Indian Journal of Nephrology, vol. 20, no. 2, pp. 80–83, 2010. View at Publisher · View at Google Scholar · View at Scopus
  282. G. W. Stone, P. A. McCullough, J. A. Tumlin et al., “Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial,” Journal of the American Medical Association, vol. 290, no. 17, pp. 2284–2291, 2003. View at Publisher · View at Google Scholar · View at Scopus
  283. D. E. Allie, M. D. Lirtzman, C. H. Wyatt et al., “Targeted renal therapy and contrast-induced nephropathy during endovascular abdominal aortic aneurysm repair: results of a feasibility pilot trial,” Journal of Endovascular Therapy, vol. 14, no. 4, pp. 520–527, 2007. View at Publisher · View at Google Scholar · View at Scopus
  284. G. Weisz, S. J. Filby, M. G. Cohen et al., “Safety and performance of targeted renal therapy: the Be-RITe! registry,” Journal of Endovascular Therapy, vol. 16, no. 1, pp. 1–12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  285. I. A. Rahman, J. G. Mascaro, R. P. Steeds et al., “Remote ischemic preconditioning in human coronary artery bypass surgery: from promise to disappointment?” Circulation, vol. 122, no. 11, pp. S53–S59, 2010. View at Publisher · View at Google Scholar · View at Scopus
  286. Z. A. Ali, C. J. Callaghan, E. Lim et al., “Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial,” Circulation, vol. 116, no. 11, pp. I98–I105, 2007. View at Publisher · View at Google Scholar · View at Scopus
  287. S. R. Walsh, U. Sadat, J. R. Boyle et al., “Remote ischemic preconditioning for renal protection during elective open infrarenal abdominal aortic aneurysm repair: randomized controlled trial,” Vascular and Endovascular Surgery, vol. 44, no. 5, pp. 334–340, 2010. View at Publisher · View at Google Scholar · View at Scopus
  288. J. Xie, X. Liao, W. Chen et al., “Remote ischaemic preconditioning reduces myocardial injury in patients undergoing heart valve surgery: randomised controlled trial,” Heart, vol. 98, no. 5, pp. 384–388, 2012. View at Publisher · View at Google Scholar · View at Scopus
  289. V. Venugopal, D. J. Hausenloy, A. Ludman et al., “Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold-blood cardioplegia: a randomised controlled trial,” Heart, vol. 95, no. 19, pp. 1567–1571, 2009. View at Publisher · View at Google Scholar · View at Scopus
  290. D. J. Hausenloy, P. K. Mwamure, V. Venugopal et al., “Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial,” The Lancet, vol. 370, no. 9587, pp. 575–579, 2007. View at Publisher · View at Google Scholar · View at Scopus
  291. K. R. Pedersen, H. B. Ravn, J. V. Povlsen, M. R. Schmidt, E. J. Erlandsen, and V. E. Hjortdal, “Failure of remote ischemic preconditioning to reduce the risk of postoperative acute kidney injury in children undergoing operation for complex congenital heart disease: a randomized single-center study,” Journal of Thoracic and Cardiovascular Surgery, vol. 143, no. 3, pp. 576–583, 2012. View at Publisher · View at Google Scholar · View at Scopus
  292. F. Er, A. M. Nia, H. Dopp, et al., “Ischemic preconditioning for prevention of contrast medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial),” Circulation, vol. 126, no. 3, pp. 296–303, 2012.
  293. A. J. Ludman, D. M. Yellon, and D. J. Hausenloy, “Cardiac preconditioning for ischaemia: lost in translation,” DMM Disease Models and Mechanisms, vol. 3, no. 1-2, pp. 35–38, 2010. View at Publisher · View at Google Scholar · View at Scopus